LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free CEL Stock Alerts GBX 102.50 -2.50 (-2.38%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 100▼ 11250-Day Range 78.50▼ 12052-Week Range 73.44▼ 180Volume42,693 shsAverage Volume41,958 shsMarket Capitalization£65.82 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 222.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines Get Celadon Pharmaceuticals alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Celadon Pharmaceuticals Stock (LON:CEL)Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.Read More CEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CEL Stock News HeadlinesApril 27, 2024 | americanbankingnews.comCeladon Pharmaceuticals (LON:CEL) Stock Price Down 2.4%February 28, 2024 | morningstar.comCeladon Pharmaceuticals PLC CELApril 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… December 14, 2023 | lse.co.ukCeladon announces start of cannabis supply for two UK companiesDecember 12, 2023 | lse.co.ukTRADING UPDATES: Celadon Pharma raises GBP2.0 million via placingDecember 4, 2023 | msn.comUK's First Medical Marijuana Clinical Trial Gets Underway: National Health Service Remains CautiousNovember 16, 2023 | lse.co.ukCeladon shares rise on supply contract worth up to GBP26 millionOctober 13, 2023 | marketwatch.comCeladon Pharmaceuticals to Raise GBP1 Mln via Discounted Placing, SubscriptionApril 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 1, 2023 | finance.yahoo.comCeladon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)September 28, 2023 | lse.co.ukCeladon Pharmaceuticals interim loss narrows; optimistic for futureSeptember 5, 2023 | lse.co.ukCeladon shares rise on second UK contract win for cannabis productSeptember 5, 2023 | marketwatch.comCeladon Pharmaceuticals Enters New Contract Worth Up to GBP1.2 Mln in RevenueAugust 22, 2023 | finance.yahoo.comOwning 61% in Celadon Pharmaceuticals Plc (LON:CEL) means that insiders are heavily invested in the company's futureAugust 1, 2023 | ca.finance.yahoo.comCEL.L - Celadon Pharmaceuticals PlcAugust 1, 2023 | lse.co.ukCeladon receives approval for 5,000 patient clinical cannabis trialJune 9, 2023 | finance.yahoo.comInvestors’ Chronicle: Oxford Metrics, N Brown, Celadon PharmaceuticalsJune 5, 2023 | lse.co.ukCeladon Pharmaceuticals loss widens; confident amid three-year dealMay 30, 2023 | lse.co.ukCeladon secures GBP7 million credit facility as product demand growsMay 30, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Rise on New GBP7 Mln Line of CreditMay 24, 2023 | lse.co.ukCeladon signs commercial cannabis supply agreement with UK firmMay 24, 2023 | lse.co.ukCORRECT: Celadon signs commercial cannabis supply agreement in UKApril 20, 2023 | finance.yahoo.comC15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech PlatformMarch 15, 2023 | finance.yahoo.comJames Short Celadon Pharmaceuticals Plc's (LON:CEL) CEO is the most bullish insider, and their stock value gained 162%last weekMarch 14, 2023 | thetimes.co.ukFresh permit for cannabis lifts CeladonMarch 14, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Jump as Sale of Pharmaceutical Cannabis Product GrantedJanuary 16, 2023 | thetimes.co.ukCeladon wins right to cultivate and make medicinal cannabis oilSee More Headlines Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:CEL CUSIPN/A CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 222.50 High Stock Price TargetGBX 235 Low Stock Price TargetGBX 210 Potential Upside/Downside+117.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-7,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-122.33% Return on Assets-35.60% Debt Debt-to-Equity Ratio153.26 Current Ratio1.86 Quick Ratio6.97 Sales & Book Value Annual Sales£11,258.00 Price / Sales5,846.09 Cash FlowGBX 33.58 per share Price / Cash Flow3.05 Book ValueGBX 5 per share Price / Book20.50Miscellaneous Outstanding Shares64,210,000Free FloatN/AMarket Cap£65.82 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. James Gareth Short (Age 56)CEO & Executive Director Comp: $246.15kMr. Jonathan Paul Turner (Age 46)CFO & Director Ms. Kerin Williams (Age 54)Company Secretary Key CompetitorsECO Animal Health GroupLON:EAHVenture Life GroupLON:VLGDiurnal GroupLON:DNLAnimalcare GroupLON:ANCRAllergy TherapeuticsLON:AGYView All Competitors CEL Stock Analysis - Frequently Asked Questions Should I buy or sell Celadon Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CEL shares. View CEL analyst ratings or view top-rated stocks. What is Celadon Pharmaceuticals' stock price target for 2024? 2 brokers have issued twelve-month price targets for Celadon Pharmaceuticals' shares. Their CEL share price targets range from GBX 210 to GBX 235. On average, they anticipate the company's stock price to reach GBX 222.50 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price. View analysts price targets for CEL or view top-rated stocks among Wall Street analysts. How have CEL shares performed in 2024? Celadon Pharmaceuticals' stock was trading at GBX 115 at the beginning of 2024. Since then, CEL shares have decreased by 10.9% and is now trading at GBX 102.50. View the best growth stocks for 2024 here. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:CEL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
